GSK's Zofran Could Lead To Abnormal Heart Rhythms: FDA

Law360, Chicago (September 16, 2011, 4:54 PM EDT) -- Use of GlaxoSmithKline PLC's anti-nausea drug Zofran and its generic equivalents may boost the risk of developing abnormal and potentially fatal heart rhythms, the U.S. Food and Drug Administration announced Thursday.

The FDA said it was conducting an ongoing safety review of the drug, used to prevent nausea and vomiting caused by chemotherapy, radiation therapy and surgery, and that the agency was making interim changes to the drug's labels.

GSK must also conduct its own study to determine whether Zofran might affect the electrical activity of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.